Overview

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2021-02-18
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Niacinamide
Sorafenib